Unicycive Therapeutics (UNCY) EBITDA Margin (2022 - 2023)
Unicycive Therapeutics posted quarterly EBITDA Margin of 622.52% for Q1 2023, down 6.59% on a QoQ basis from 584.02% in Q3 2022.
Unicycive Therapeutics (UNCY) has 2 years of EBITDA Margin data on file, last reported at 622.52% in Q1 2023.
- For the quarter ending Q1 2023, EBITDA Margin changed N/A year-over-year to 622.52%; the trailing twelve-month figure through Dec 2023 stood at 3077.78% (changed N/A YoY), and the FY2023 full-year result was 3077.63%, down 117942.0% from the prior year.
- EBITDA Margin for Q1 2023 stood at 622.52%, down from 584.02% in the prior quarter.
- Across five years, EBITDA Margin topped out at 584.02% in Q3 2022 and bottomed at 622.52% in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -622.52% |
| Sep 30, 2022 | -584.02% |